Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorVarinelli, Luca
dc.contributor.authorDi Bella, Marzia
dc.contributor.authorGuaglio, Marcello
dc.contributor.authorBattistessa, Davide
dc.contributor.authorPisati, Federica
dc.contributor.authorCavalleri, Tommaso
dc.contributor.authorMartinez-Quintanilla, Jordi
dc.date.accessioned2025-02-18T10:48:47Z
dc.date.available2025-02-18T10:48:47Z
dc.date.issued2024-11
dc.identifier.citationVarinelli L, Di Bella M, Guaglio M, Battistessa D, Pisati F, Cavalleri T, et al. A combinatorial culture strategy to develop pseudomyxoma peritonei organoid models. J Surg Oncol. 2024 Nov;130(6):1213–24.
dc.identifier.issn1096-9098
dc.identifier.urihttps://hdl.handle.net/11351/12614
dc.descriptionAppendiceal tumors; Organoids; Pseudomyxoma peritonei
dc.description.abstractBackground and Objectives Few preclinical models of pseudomyxoma peritonei (PMP) have been developed, probably due to the tumor's low incidence and its peculiar characteristics of slow growth. Therefore, there is a need to develop more refined PMP models that better reflect its characteristics. The aim of the study is to develop a culture strategy to generate organoid models derived from PMP patient samples. Methods We followed a strategy based on combinatorial culture conditions that include the different factors essential for PMP growth and that mimic the microenvironment present in the patients. Results We cultured PMP samples in the presence of the various factors produced by the niche environment of PMP. We obtained 12 PMP organoid models, each of which grows under specific culture conditions. PMP-derived organoids show long-term expansion capacity and reproduce the genetic landscape and histological phenotype of the tumor of origin. Conclusion The organoids we developed faithfully reproduce the key features of PMP disease and will allow us to understand the biology of PMP. With them, we will be able to identify key regulatory networks that support PMP progression, providing a platform for multilevel preclinical testing, identify novel diagnostic biomarkers, and generate novel targets for patient treatments.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesJournal of Surgical Oncology;130(6)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectCultiu cel·lular
dc.subjectMucines
dc.subjectImatgeria tridimensional en medicina
dc.subjectPeritoneu - Càncer
dc.subject.meshPeritoneal Neoplasms
dc.subject.meshOrganoids
dc.subject.meshPseudomyxoma Peritonei
dc.subject.meshTumor Cells, Cultured
dc.titleA combinatorial culture strategy to develop pseudomyxoma peritonei organoid models
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/jso.27850
dc.subject.decsneoplasias peritoneales
dc.subject.decsorganoides
dc.subject.decsseudomixoma peritoneal
dc.subject.decscélulas tumorales cultivadas
dc.relation.publishversionhttps://doi.org/10.1002/jso.27850
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Varinelli L, Di Bella M, Battistessa D] Molecular Epigenomics Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. [Guaglio M, Cavalleri T] Peritoneal Surface Malignancies Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. [Pisati F] Cogentech Ltd. Benefit Corporation with a Sole Shareholder, Milan, Italy. [Martínez‐Quintanilla J] Translational Program, Stem Cells and Cancer Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid39360464
dc.identifier.wos001324610900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record